Sign In
Buy MRNA
$51.59
+2.53 (+5.16%)
At Close: Jun 04, 2026
Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to Know
11:02am, Thursday, 12'th Sep 2024
Moderna stock is plunging Thursday after the COVID-19 vaccine maker announced plans to drastically cut its R&D spending to focus on new product approvals.
Moderna CEO explains why the company is going to cut $1.1 billion in costs by 2027
11:01am, Thursday, 12'th Sep 2024
Moderna CEO Stephane Bancel on plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline of its Covid business
The Schall Law Firm Seeks Investor Participation In A Securities Fraud Case Against Moderna, Inc.
11:00am, Thursday, 12'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or
Shareholders That Lost Money on Moderna, Inc. (MRNA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
10:30am, Thursday, 12'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 12, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, f
Moderna shares tank after announcing $1.1bn cost-cutting measures
10:27am, Thursday, 12'th Sep 2024
US pharmaceuticals giant Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares tanked more than 17% on Thursday after announcing a $1.2 billion cost-cutting plan in its research and development department. Modern
MRNA Stumbles on Spending Cut, OpenAI Asks for Investor Funding, KR Up After Earnings
10:27am, Thursday, 12'th Sep 2024
While Kroger (KR) shares are higher after mixed earnings, Moderna (MRNA) tumbled off its plans to cut back on costs and production of its products. Meanwhile, OpenAI eyes additional funds from investo
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna
10:02am, Thursday, 12'th Sep 2024
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Moderna To Contact Him Directly To Discuss Their Options If you su
Why is Moderna's stock crashing today? Here's what we know
09:48am, Thursday, 12'th Sep 2024
Moderna Inc. (NASDAQ: MRNA) saw its stock plunge more than 14% on Thursday, following the company's announcement of significant cuts to its annual research and development (R&D) expenses. The biotech
Moderna Stock Drops on Plans To Cut $1.1B in R&D Costs
09:25am, Thursday, 12'th Sep 2024
Moderna (MRNA) shares tumbled in pre-market trading Thursday as the company said it plans to cut costs and suspend or end development of some products as it focuses on later-stage trials.
Moderna CEO: Plan to file Covid and flu combo shot with FDA by end of the year
07:53am, Thursday, 12'th Sep 2024
Stephane Bancel, Moderna CEO, joins 'Squawk Box' to discuss Moderna's recent stock performance, what could explain the stock's underperformance, and much more.
Levi & Korsinsky Reminds Moderna Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024 - MRNA
07:15am, Thursday, 12'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 12, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, f
MRNA Stockholders Have Opportunity to Lead Moderna, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
07:00am, Thursday, 12'th Sep 2024
NEW YORK CITY, NY / ACCESSWIRE / September 12, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Modern
Moderna expects up to $3.5 billion in 2025 sales
06:14am, Thursday, 12'th Sep 2024
Moderna on Thursday said it expects sales of between $2.5 billion and $3.5 billion next year, and forecast that new product launches would drive an average annual growth rate of 25% in revenue between
Moderna slashes research spending, trims pipeline as it looks to regain footing
06:02am, Thursday, 12'th Sep 2024
Moderna Inc. on Thursday touted progress toward new vaccine approvals but said it will rein in its research and development spending and trim its pipeline as it looks to shake off the doldrums of a dw
Moderna to cut $1.1 billion in costs and launch 10 new products by 2027 as it charts post-Covid future
06:00am, Thursday, 12'th Sep 2024
Moderna said it plans to cut $1.1 billion in expenses by 2027 as it charts a path forward after the rapid decline of its Covid business. The biotech company said it expects 10 new product approvals
